ClinVar Miner

Submissions for variant NM_002485.5(NBN):c.1036G>A (p.Val346Met)

gnomAD frequency: 0.00016  dbSNP: rs200297914
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 16
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000589164 SCV000149685 likely benign not provided 2020-11-25 criteria provided, single submitter clinical testing This variant is associated with the following publications: (PMID: 23525077, 26976419, 27443514, 23555315)
Ambry Genetics RCV000115776 SCV000186073 likely benign Hereditary cancer-predisposing syndrome 2020-09-28 criteria provided, single submitter clinical testing In silico models in agreement (benign);Other data supporting benign classification
Invitae RCV001082179 SCV000261858 likely benign Microcephaly, normal intelligence and immunodeficiency 2021-12-15 criteria provided, single submitter clinical testing
Eurofins NTD LLC (GA) RCV000589164 SCV000341709 uncertain significance not provided 2016-04-27 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000212741 SCV000697932 likely benign not specified 2021-01-09 criteria provided, single submitter clinical testing Variant summary: NBN c.1036G>A (p.Val346Met) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.0003 in 251374 control chromosomes, predominantly at a frequency of 0.0033 within the East Asian subpopulation in the gnomAD database. The observed variant frequency within East Asian control individuals in the gnomAD database is approximately 1.3 fold of the estimated maximal expected allele frequency for a pathogenic variant in NBN causing Nijmegen Breakage Syndrome phenotype (0.0025), strongly suggesting that the variant is a benign polymorphism found primarily in populations of East Asian origin. c.1036G>A has been reported in the literature in individuals affected with breast cancer, endometrial cancer and in unaffected controls (example, Haiman_2013, Tung_2016, Ring_2016, Momozawa_2018). These report(s) do not provide unequivocal conclusions about association of the variant with Nijmegen Breakage Syndrome or with any of the NBN associated tumors. At-least two co-occurrences with other pathogenic variant(s) have been observed at our laboratory (APC c.1206_1207delTG, p.Glu403AsnfsX15; BRCA2 c.6405_6409delCTTAA, p.Asn2135LysfsX3), providing additional supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Nine clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (likely benign, n=6 and VUS, n=3). Some submitters cite overlapping evidence utilized in the context of this evaluation. Based on evidence supporting the emerging consensus outlined above, the variant was re-classified as likely benign.
Color Diagnostics, LLC DBA Color Health RCV000115776 SCV000902682 likely benign Hereditary cancer-predisposing syndrome 2015-11-18 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000589164 SCV001134492 likely benign not provided 2019-04-18 criteria provided, single submitter clinical testing
Illumina Laboratory Services,Illumina RCV001082179 SCV001321724 uncertain significance Microcephaly, normal intelligence and immunodeficiency 2018-01-13 criteria provided, single submitter clinical testing This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease.
ACT Genomics, RCV001255161 SCV001366120 likely benign Malignant tumor of prostate 2020-06-22 criteria provided, single submitter clinical testing The allele frequency of this variant c.1036G>A (p.Val346Met) is 0.003 in East Asian of gnomAD Exomes and 0.002 in East Asian in 1000 Genomes. There is a small physicochemical difference between valine and methionine, which is not likely to impact secondary protein structure as these residues share similar properties. The variant is predicted to be tolerated by both SIFT or PolyPhen2. For these reasons, this variant has been classified as Likely Benign.
Baylor Genetics RCV001293998 SCV001482744 uncertain significance Aplastic anemia 2020-11-23 criteria provided, single submitter clinical testing This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868].
Genome-Nilou Lab RCV001082179 SCV002045941 likely benign Microcephaly, normal intelligence and immunodeficiency 2021-11-07 criteria provided, single submitter clinical testing
Genetic Services Laboratory,University of Chicago RCV000212741 SCV002068221 uncertain significance not specified 2018-04-27 criteria provided, single submitter clinical testing
Sema4,Sema4 RCV000115776 SCV002536566 likely benign Hereditary cancer-predisposing syndrome 2020-11-05 criteria provided, single submitter curation
Natera, Inc. RCV001082179 SCV001457044 likely benign Microcephaly, normal intelligence and immunodeficiency 2020-01-03 no assertion criteria provided clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV001355371 SCV001550243 uncertain significance Malignant tumor of breast no assertion criteria provided clinical testing The NBN p.Val346Met variant was identified in 1 of 976 proband chromosomes (frequency: 0.001) from individuals or families with breast cancer (Tung 2016). The variant was also identified in the following databases: dbSNP (ID: rs200297914) as “With Uncertain significance allele”, in ClinVar (classified with conflicting interpretations of pathogenicity; submitters: likely benign by Invitae and uncertain significance by GeneDx, Ambry Genetics, EGL Genetic Diagnostics and Laboratory Corporation of America), Clinvitae (4x), Cosmic (1x in an adenocarcinoma of the oesophagus), and not identified in LOVD 3.0 and Zhejiang University Database. The variant was identified in control databases in 77 of 277100 chromosomes at a frequency of 0.0003 (Genome Aggregation Database Feb 27, 2017). It was observed in the following populations: Latino in 3 of 34386 chromosomes (freq: 0.00009), European Non-Finnish in 2 of 126628 chromosomes (freq: 0.00002), East Asian in 62 of 18866 chromosomes (freq: 0.003), and South Asian in 10 of 30782 chromosomes (freq: 0.0003); it was not observed in the African, Other, Ashkenazi Jewish and Finnish populations. The p.Val346 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact of the variant Met to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and 2 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.
Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C. RCV000115776 SCV001977055 likely benign Hereditary cancer-predisposing syndrome 2021-09-27 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.